Drug Trial Radar · NCT07708727
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Jul 29, 2026
Primary completion
Oct 2030
Study completion Apr 2033
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B. The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)), in people with HIV-1 (PWH) who are new to treatment. This will be done in Treatment Groups 1, 2 and 3 at Week 35. The goal of Phase 2, Part B is to compare the effectiveness of study drugs, GS-3242 and LEN versus B/F/TAF in Groups 4 and 3 at Week 26. The goal of Phase 3 is to assess the long-term effectiveness of study drug GS-3242 and LEN versus B/F/TAF, at Week 52. The primary objectives of this study are: Phase 2, Part A: To evaluate the efficacy of intramuscular (IM) GS-3242 plus IM LEN versus B/F/TAF in treatment-naive people with HIV-1 (PWH) in Treatment Groups 1, 2, and 3 at Week 35. Phase 2, Part B: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH in Treatment Groups 4 and 3 at Week 26. Phase 3: To evaluate the efficacy of IM GS-3242 plus IM LEN versus B/F/TAF in treatment-naive PWH at Week 52.
Conditions
- HIV-1-infection
Interventions
GS-3242 TabletDrug
Administered orally
GS-3242 InjectionDrug
Administered intramuscularly (IM)
Lenacapavir TabletDrug
Administered orally
Lenacapavir InjectionDrug
Administered IM
B/F/TAFDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Part A: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 35 as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 35
- Phase 2: Part B: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 26 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 26
- Phase 3: Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot AlgorithmTime frame: Week 52
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
Lundquist Inst Biomedical Innovation Harbor-UCLA
Torrance, California · Recruiting
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut · Recruiting
Midway Immunology and Research Center
Ft. Pierce, Florida · Recruiting
Floridian Clinical Research, LLC
Miami Lakes, Florida · Recruiting
Orlando Immunology Center, PA
Orlando, Florida · Recruiting
Triple O Research Institute, P.A.
West Palm Beach, Florida · Recruiting
Emory University Hospital Midtown Infectious Disease Clinic
Atlanta, Georgia · Recruiting
Metro Infectious Disease Consultants, P.L.L.C
Decatur, Georgia · Recruiting
KC care Health Center
Kansas City, Missouri · Recruiting
Saint Michael's Medical Center
Newark, New Jersey · Recruiting
St Hope Foundation, Inc,
Bellaire, Texas · Recruiting
Prism Health North Texas
Dallas, Texas · Recruiting
North Texas Infectious Diseases Consultants, PA
Dallas, Texas · Recruiting
Texas Centers for Infectious Disease Associates
Fort Worth, Texas · Recruiting
MultiCare Health System - Deaconess Medical Office Building 2
Spokane, Washington · Recruiting
McGill University Health Centre
Decarie Montreal, Canada · Recruiting
CHU de Québec-Université Laval
Québec, Canada · Recruiting
ICH Study Center GmbH & Co. KG
Hamburg, Germany · Not yet recruiting
Proyecto ACTU
Rio Piedras, PR, Puerto Rico · Recruiting
HOPE Clinical Research
San Juan, PR, Puerto Rico · Recruiting
Hospital Universitario Virgen de las Nieves
Granada, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.